
## Tereza Suchankova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7338961/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transcription factor c-Myb: novel prognostic factor in osteosarcoma. Clinical and Experimental Metastasis, 2022, 39, 375-390.	1.7	4
2	Toll-Like Receptor 3 Overexpression Induces Invasion of Prostate Cancer Cells, whereas Its Activation Triggers Apoptosis. American Journal of Pathology, 2022, 192, 1321-1335.	1.9	3
3	The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxelâ€resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. Molecular Oncology, 2020, 14, 2487-2503.	2.1	13
4	High Skp2 expression is associated with a mesenchymal phenotype and increased tumorigenic potential of prostate cancer cells. Scientific Reports, 2019, 9, 5695.	1.6	21
5	Presence of growth/differentiation factor-15 cytokine in human follicular fluid, granulosa cells, and oocytes. Journal of Assisted Reproduction and Genetics, 2018, 35, 1407-1417.	1.2	7
6	Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation. Molecular Cancer Therapeutics, 2017, 16, 1831-1842.	1.9	17
7	MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated. Nature Communications, 2016, 7, 13701.	5.8	36
8	Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells. Oncotarget, 2015, 6, 36156-36171.	0.8	17
9	The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells. Molecular Cancer, 2014, 13, 113.	7.9	24
10	Conformation and recognition of DNA damaged by antitumor cis-dichlorido platinum(II) complex of CDK inhibitor bohemine. European Journal of Medicinal Chemistry, 2014, 78, 54-64.	2.6	10
11	DNA conformation and repair of polymeric natural DNA damaged by antitumor azolato-bridged dinuclear PtII complex. Journal of Inorganic Biochemistry, 2012, 114, 15-23.	1.5	22
12	Platinum–DNA interstrand crosslinks: Molecular determinants of bending and unwinding of the double helix. Journal of Inorganic Biochemistry, 2012, 108, 69-79.	1.5	17
13	Unique DNA Binding Mode of Antitumor Trinuclear Tridentate Platinum(II) Compound. Molecular Pharmaceutics, 2011, 8, 2368-2378.	2.3	25
14	Conformation and recognition of DNA modified by a new antitumor dinuclear PtII complex resistant to decomposition by sulfur nucleophiles. Biochemical Pharmacology, 2010, 79, 112-121.	2.0	33
15	Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring PtII chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand. Biochemical Pharmacology, 2010, 79, 552-564.	2.0	48
16	Mechanistic insights into antitumor effects of new dinuclear cis PtII complexes containing aromatic linkers. Biochemical Pharmacology, 2010, 80, 344-351.	2.0	21
17	Energetics, Conformation, and Recognition of DNA Duplexes Modified by Monodentate Ru <sup>II</sup> Complexes Containing Terphenyl Arenes. Chemistry - A European Journal, 2010, 16, 5744-5754.	1.7	24
18	Different Features of the DNA Binding Mode of Antitumor <i>cis</i> -Amminedichlorido(cyclohexylamine)platinum(II) (JM118) and Cisplatin in Vitro. Chemical Research in Toxicology, 2010, 23, 1833-1842.	1.7	21

#	Article	IF	CITATIONS
19	DNA and glutathione interactions in cell-free media of asymmetric platinum(II) complexes cis- and trans-[PtCl2(isopropylamine)(1-methylimidazole)]: relations to their different antitumor effects. Journal of Biological Inorganic Chemistry, 2009, 14, 75-87.	1.1	17